Lets talk molecule shape first, aleniglipron is what is known in the pharma spaces as a me too drug. That is generally understood as targeting the same receptor as a known drug for similar effects, in this case targeting the GLP-1 receptor for treatment of obesity and diabetes
Beyond Parkinsons, L-DOPAs therapeutic potential extends to neurodegenerative conditions such as Alzheimers disease, Huntingtons disease, multiple sclerosis, Lewy body dementia, and amyotrophic lateral sclerosis, where dopamine modulation plays a critical role
Yet, the potential of such approaches may be contingent upon individual variations in MC1R function and expression, highlighting the need for further research to fully understand and leverage MC1R's protective mechanisms in skin cells
Please check the legal requirements about buying peptides in your home country